Nanxin (Nick) Li, PhD, MBA is a value and access leader in building global and US HEOR functions, integrating HEOR into development and commercialization process, optimizing product value proposition throughout life cycle, and delivering reimbursement successes for innovative products. Nick has a solid track record of making impacts on business. He currently leads HEOR function at uniQure to demonstrate value of gene therapy pipeline products and enable optimal access to these therapies for patients; most recently, he led HEOR efforts at Bioverativ for rare blood disorder franchise, including global launch of the first extended half-life hemophilia products Eloctate and Alprolix. He has also worked on other major brands in multiple therapeutic areas, including hematology/oncology, rheumatology, cardiovascular, and metabolic diseases.
He has published more than 50 manuscripts in peer-reviewed journals including Science, PNAS, and PharmacoEconomics, and served on the editorial advisory board of Journal of Comparative Effectiveness Research and as a reviewer for many other leading clinical and health economics journals.